Aperture Venture Partners

Type

Venture Capital

Status

Active

Location

New York, United States

Total investments

58

Average round size

36M

Portfolio companies

37

Rounds per year

2.64

Lead investments

4

Follow on index

0.36

Exits

22

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsWellnessMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsWomen's

Summary

Aperture Venture Partners appeared to be the VC, which was created in 2002. The venture was found in North America in United States. The main department of described VC is located in the New York.

This organization was formed by Eric H. Sillman. Besides them, we counted 3 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Aperture Venture Partners, startups are often financed by Lumira Ventures, TPG Biotech, Vivo Capital. The meaningful sponsors for the fund in investment in the same round are Third Point Ventures, Vivo Capital, Lumira Ventures. In the next rounds fund is usually obtained by Third Point Ventures, OrbiMed, Ziegler Meditech Equity Partners.

Opposing the other organizations, this Aperture Venture Partners works on 17 percentage points more the average amount of lead investments. The increased amount of exits for fund were in 2015. The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2015. Despite it in 2019 the fund had an activity.

The fund has specific favorite in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight MAKO Surgical, Cardiac Dimensions, Channel Medsystems. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Food and Beverage, Therapeutics.

Show more

Investor highlights

Industry focus
HealthcareMedtechBiotech/Life Sciences

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
58
Lead investments
4
Exits
22
Rounds per year
2.64
Follow on index
0.36
Investments by industry
  • Health Care (51)
  • Biotechnology (36)
  • Medical Device (26)
  • Medical (26)
  • Therapeutics (13)
  • Show 24 more
Investments by region
  • United States (55)
  • Israel (3)
Peak activity year
2015
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
18
Avg. valuation at time of investment
86M
Group Appearance index
0.97
Avg. company exit year
12
Avg. multiplicator
2.00
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Clutch 04 Aug 2022 Apps, Digital Marketing, Marketing, Social Media, Professional Services Seed 1M United States, Texas, Houston
Miach Orthopaedics 02 Apr 2024 Biotechnology, Health Care, Wellness, Manufacturing, Medical Device, Medical Early Stage Venture 20M United States, Massachusetts, Boston
V-Wave 22 Sep 2020 Biotechnology, Health Care, Medical Device, Medical Late Stage Venture 28M North District, Israel, Israel

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.